Related Experiment Video

Updated: Feb 8, 2026

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

9.2K

Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma

Xiaolong Tang1, Longzhou Chen2, Amin Li1

  • 1a Medical College , Anhui University of Science and Technology , Huainan , China.

Drug Delivery
|June 20, 2018
PubMed

Insights

This study developed targeted nanoparticles loaded with sorafenib (SFB) to treat liver cancer (HCC). These novel nanoparticles show improved drug delivery, enhanced tumor cell killing, and reduced side effects, offering a promising new therapy.

Area of Science:

  • Biotechnology
  • Nanomedicine
  • Oncology

Background:

  • Sorafenib (SFB) is a key treatment for hepatocellular carcinoma (HCC), but its efficacy is limited by poor tumor targeting.
  • Achieving sustained therapeutic drug concentrations within tumors remains a challenge for current HCC treatments.

Purpose of the Study:

  • To develop a novel, targeted nanoparticle system for improved delivery of sorafenib (SFB) in hepatocellular carcinoma (HCC) treatment.
  • To enhance the anti-cancer efficacy and reduce systemic toxicity of SFB through targeted delivery.

Main Methods:

  • Synthesized SFB-loaded polymer nanoparticles (NPs) using TPGS-b-PCL copolymer, incorporating Pluronic P123 and SFB.
  • Conjugated anti-GPC3 antibodies to the NP surface (NP-SFB-Ab) for targeted delivery to HCC cells.
  • Evaluated cellular uptake, stability, drug release, cytotoxicity, apoptosis induction, and in vivo tumor growth inhibition in HCC models.

Main Results:

  • NP-SFB-Ab demonstrated significantly higher cellular uptake in HepG2 cells compared to non-targeted NPs (NP-SFB).
  • NP-SFB-Ab exhibited enhanced stability, increased SFB release, and superior cytotoxicity against tumor cells.
  • The targeted NPs induced apoptosis by downregulating MCL-1 and promoting cytochrome C release, significantly inhibiting tumor growth in vivo with minimal side effects.

Conclusions:

  • The novel antibody-conjugated nanoparticle system (NP-SFB-Ab) effectively targets and delivers SFB to HCC cells, enhancing therapeutic outcomes.
  • This targeted nanoparticle approach represents a promising strategy for improving the efficacy and safety of HCC treatment.
Keywords:
Hepatocellular carcinomaanti-GPC3 antibodynanoparticlessorafenibtargeted delivery

More Related Videos

Exploring the Potential of Mesenchymal Stem Cell Sheet on The Development of Hepatocellular Carcinoma In Vivo10:18

Exploring the Potential of Mesenchymal Stem Cell Sheet on The Development of Hepatocellular Carcinoma In Vivo

Published on: September 11, 2018

6.2K
A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis05:06

A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis

Published on: October 24, 2015

12.9K

Related Concept Videos

Feedback Inhibition00:46

Feedback Inhibition

Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
57.2K
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
92.6K
Antibody Structure01:10

Antibody Structure

Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
65.7K
Impact Loading01:19

Impact Loading

Impact loading occurs when a moving object collides with a stationary structure, such as a rod with a uniform cross-sectional area fixed at one end. Under these conditions, the rod absorbs the kinetic energy from the striking object, leading to deformation and subsequent stress development. As the rod returns to its original position and reaches maximum stress, the absorbed energy, initially manifested as kinetic energy, transforms entirely into strain energy.
In cases of elastic deformation,...
710
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K
Distributed Loads01:19

Distributed Loads

Distributed loads are a common type of load that engineers and scientists encounter in various practical situations. Distributed loads often refer to a type of load spread over a surface or a structure and can be modeled as continuous force per unit area.
For example, consider a bookshelf filled with books stacked vertically adjacent to each other. The weight of the books is evenly distributed over the length of the shelf. As a result, the pressure at different locations on the surface of the...
978